We have previously found that T lymphocytes are essential for development of angiotensin II-induced hypertension; however, the mechanisms responsible for T-cell activation in hypertension remain undefined. Objective: We sought to study the roles of the CNS and pressure elevation in T-cell activation and vascular inflammation caused by angiotensin II.
T he CNS plays an integral role in blood pressure regulation, primarily through sympathetic activation and mediation of various neurohumoral factors such as angiotensin II (Ang II) and vasopressin. [1] [2] [3] [4] Hormones such as these can access the circumventricular organs, which are adjacent to the cerebral ventricles and have a poorly formed blood brain barrier. The circumventricular organs implicated in blood pressure control include the organum vasculosum of the lamina terminalis (OVLT), the area postrema, the subfornical organ, and the anteroventral third ventricle (AV3V) region. 5 The AV3V region includes the median preoptic nucleus, the OVLT, and the periventricular nucleus and has been shown to play an important role in several behavioral, neural and hormonal functions involved in body fluid and cardiovascular homeostasis. 6, 7 Electrolytic lesions that disrupt the AV3V region have been shown to abolish virtually all of the central actions of Ang II, including drinking behavior, sympathetic outflow, and vasopressin release. 6 Electrolytic lesions of this brain region abolish the centrally mediated pressor response to central and peripheral infusions of Ang II, as well as preventing and/or reversing several other forms of experimental hypertension. 5, 6 In addition to central mechanisms, substantial evidence suggests that inflammation can contribute to the pathophysiology of hypertension. For example, inflammatory cells accumulate in the kidney and vasculature of hypertensive animals, and the prevention of this can lower blood pressure. 8 Recently, our laboratory has found that mice lacking T-lymphocytes are resistant to the development of both Ang II and DOCA-salt induced hypertension. 9 Adoptive transfer of T, but not B cells restored hypertension in these animals. Despite the growing evidence for the role of T cells in hypertension, the mechanisms underlying T-cell activation and vascular infiltration by T cells remain unclear. Given the importance of the CNS in regulating blood pressure, we hypothesized that the CNS could participate in activation of peripheral T cells and contribute to vascular inflammation in response to Ang II. We tested this hypothesis by producing electrolytic lesions of the AV3V region in mice and then examined properties of circulating T cells and the vascular accumulation of these cells in response to chronic Ang II infusion. We also examined the role of pressure elevation in T-cell activation and vascular inflammation. Our findings provide a new understanding for how the CNS, in particular the circumventricular organs, can contribute to the promotion of systemic inflammation in hypertension.
Methods
Animals C57BL/6, RAG-1 Ϫ/Ϫ and ovalbumin (OVA)-specific, MHC class II-restricted ␣/␤ T-cell receptor (TCR) transgenic mice (OT-II) were obtained from The Jackson Laboratory.
Production of Hypertension
Using an osmotic minipump (Alzet, Model 2002), either Ang II (490 ng ⅐ kg Ϫ1 ⅐ min Ϫ1 ), norepinephrine (3.8 g ⅐ kg Ϫ1 ⅐ min Ϫ1 ), or vehicle was infused for 14 days. Blood pressure was measured by radiotelemetry or tail cuff method, as described previously. 9 When radiotelemetry was used, the transmitters were implanted 1 week before the minipumps. In some experiments, hydralazine (250 mg/L) was administered in the drinking water to prevent the development of hypertension. 10 Adoptive transfer of T cells into RAG-1 Ϫ/Ϫ mice was performed using methods similar to those described previously 9 and norepinephrine or vehicle infusion initiated 3 weeks later.
AV3V Lesions
Mice were anesthetized with intraperitoneal ketamine and acepromazine (90 mg/kg and 1.8 mg/kg, respectively) and mounted in a stereotaxic frame with skull level between bregma and lambda. Using aseptic technique, a small hole was drilled in the skull, the midsagittal sinus was retracted, and a 200-m diameter tungsten electrode (AM Systems), Teflon-insulated except at the tip, was inserted at the midline 0.4-mm anterior to bregma and 4.8 mm ventral to the dura. 11 Lesions were produced by passing a 1.0-mA DC anodal current through the electrode for 3 seconds. Surgery for sham-operated mice was identical except that the electrode was lowered only 4.0 mm, and no current was applied. Because AV3Vlesioned animals do not drink water for several days after lesioning, mice were given a highly palatable 10% sucrose solution before and after lesioning to induce voluntary fluid intake and prevent dehydration. Following the lesion, AV3V-lesioned mice were weaned onto normal drinking water by gradually reducing the concentration of sucrose over a 2-week period. 7
AV3V Lesion Verification
Electrolytic lesioning in and around the third ventricle can produce neuronal destruction of variable extent as shown by the topography detailed in previous studies using AV3V-lesioned animals. 5, [12] [13] [14] Mice included in the AV3V-lesioned groups were functionally and histologically characterized as having sustained complete AV3V lesions using criteria (drinking behavior and histology) that were independent of the dependent variables of interest in these studies (blood pressure, superoxide production, T-cell function). Mice were considered to have complete AV3V lesions if they met the following 3 criteria: (1) failed to drink any water within 24 hours following surgery; (2) drank less than 1.0 mL of water within 2.0 hours following subcutaneous injection of 6.0% NaCl; and (3) histological confirmation following the experimental protocol of complete destruction of the AV3V region, including the OVLT, median preoptic and periventricular nuclei ( Figure  1 ). Approximately 50% of mice that received AV3V lesions met the above criteria. In the AV3V mice that met these criteria, the 24-hour water intake was 0.08Ϯ0.03 mL compared to 2.65Ϯ0.27 mL in the sham-operated group, whereas the drinking volume in response to the hypertonic 6.0% NaCl thirst challenge was 0.56Ϯ0.17 and 2.16Ϯ0.13 mL in the AV3V-lesioned and shamoperated mice, respectively.
Superoxide Measurements, Fluorescent Cell Sorting, and Analysis of Cellular Inflammation
Ϫ⅐ production was measured by quantifying formation of 2-hydroxyethidium from dihydroethidium (25 mol/L) by HPLC as described previously. 15 Analysis of circulating T cells from the blood and inflammatory cells in vascular homogenates of the aorta was performed using fluorescent cell sorting as described previously. 9 Antibodies used for staining were as follows: FITC anti-CD45 (30-F11); APC anti-CD4 (GK1.5); PerCP anti-CD8 (53-6.7); APC anti-CD3 (145-2C11); FITC CD44 (IM7); FITC CD69 (H1.2F3). After immunostaining, cells were resuspended in FACS buffer (0.5% BSA in PBS) and analyzed immediately on a LSR-II flow cytometer with DIVA software (Becton Dickinson). Data were analyzed with FlowJo software (Tree Star Inc). The institutional Animal Care and Use Committee at Emory University approved all of the above experimental protocols.
Data Presentation and Statistical Analysis
Summary data are expressed as the meansϮSEM, and values of PϽ0.05 were considered statistically significant. Comparisons between groups of animals or treatments were made by ANOVA. The Bonferroni post hoc test was used to make comparisons.
Results

Effects of AV3V Ablation on Blood Pressure and Vascular Superoxide
In sham-operated mice, Ang II infusion produced a progressive rise in blood pressure when measured either by tail cuff or radiotelemetry (Figure 2A through 2C ). Infusion of vehicle alone had no effect on arterial pressure (Figure 2A ). AV3V ablation did not affect baseline blood pressure but markedly reduced the hypertension produced by peripheral infusion of Ang II compared to the shamoperated group (Figure 2A through 2C ). Ang II infusion in AV3V-lesioned mice produced a small rise in blood pressure after 7 and 14 days compared to sham vehicle ( Figure 2A ). In other groups of mice, direct measurement of arterial pressure by radiotelemetry largely confirmed the results obtained using the tail cuff method. AV3V lesions virtually eliminated increases in systolic and diastolic blood pressure normally produced by peripheral infusion of Ang II ( Figure 2B and 2C ). Previous studies from our laboratory have shown that chronic Ang II infusion increased vascular O 2
Ϫ⅐ production. 9, 16 We confirmed these results in C57BL/6 mice without CNS lesions, as shown in Figure 2D . Chronic infusion of Ang II in sham-operated mice elevated aortic superoxide levels to values similar to those without CNS lesions. In contrast, vascular superoxide levels of mice given Ang II were significantly reduced by AV3V lesioning and were not different from mice that did not receive Ang II infusion ( Figure 2D ).
Effects of AV3V Ablation on T-Cell Activation and Vascular Inflammation
Consistent with previous observations, [17] [18] [19] Ang II infusion in sham-operated mice increased the percentage of circulating helper (CD4 ϩ ) T cells that expressed the early activation marker CD69 ( Figure 3A ) and the tissue-homing marker CD44 high ( Figure 3B ). This increase in activated CD4 ϩ T cells was abolished by AV3V lesioning ( Figure 3A and 3B). In sham-operated mice, Ang II infusion promoted vascular infiltration by inflammatory leukocytes, as evidenced by aortic accumulation of total CD45 ϩ leukocytes ( Figure 3C ) and CD3 ϩ T cells ( Figure 3D ). Similar to the results observed for circulating lymphocytes, vascular accumulation of inflammatory cells was completely prevented by the AV3V lesion. These data indicate that Ang II-induced activation of circulating T cells and infiltration of vascular tissue by inflammatory cells cannot be ascribed to a direct action of the circulating hormone on peripheral tissues but, instead, must be mediated by a CNS action of Ang II that is dependent on the AV3V region.
Effect of AV3V Ablation on Norepinephrine-Induced Hypertension, T-Cell Activation, and Vascular Inflammation
Systemic infusion of the peripherally acting vasoconstrictor norepinephrine was used as a positive control for any potential nonspecific or detrimental effects of the AV3V lesion on cardiovascular function. As shown in Figure 4A , AV3V lesions had no effect on hypertension produced by norepinephrine. When immune cell activation and vascular inflam- mation were measured, similar increases in circulating T cells expressing the early activation marker CD69 and the tissuehoming marker CD44 high were observed in both AV3Vlesioned and sham-operated animals ( Figure 4B and 4C) . Moreover, norepinephrine infusion also promoted vascular inflammation assessed by aortic accumulation of CD45 ϩ leukocytes and CD3 ϩ T cells, irrespective of whether mice had sustained AV3V lesions or not ( Figure 4C through 4E) .
These results indicate that AV3V lesions do not impair the production of hypertension and T-cell activation produced by a peripherally acting stimulus. We further confirmed that, as in the case of Ang II, T cells largely mediate the hypertensive response to norepinephrine, because the blood pressure elevation to this catecholamine was mark-edly reduced in RAG-1 Ϫ/Ϫ mice and restored by adoptive transfer of T cells ( Figure 4F ).
Effect of Preventing Hypertension With Hydralazine on Vascular Superoxide, T-Cell Activation, and Vascular Inflammation
Results from the previous experiments using Ang II and norepinephrine infusion to produce hypertension suggest that immune cell activation may be more dependent on elevated arterial pressure per se, rather than the specific stimulus that produces it. To determine whether the reduction in T-cell activation and vascular inflammation following AV3V ablation and Ang II infusion was a consequence of preventing hypertension, we administered hydralazine via the drinking water during Ang II infusion. Following 2 weeks of Ang II infusion, hydralazine eliminated the elevation in blood pressure to Ang II ( Figure 5A ), as well as vascular superoxide production ( Figure 5B ). Hydralazine also prevented the activation of circulating T cells ( Figure 5C and 5D ), as well as vascular accumulation of inflammatory cells ( Figure 5E and 5F). We also examined the effect of hydralazine administration during norepinephrine infusion. As in the case of Ang II, hydralazine prevented the increase in arterial pressure and T-cell activation and infiltration during norepinephrineinduced hypertension (Online Figure I , available at http://circres.ahajournals.org).
The effects of hydralazine on T-cell activation and vascular inflammation could be related to its antihypertensive actions or, alternatively, to a direct effect on T cells that might prevent their activation. To distinguish between these possi-bilities, we performed studies using OT-II mice. OT-II mice are transgenic for a T-cell receptor that induces production of CD4 ϩ activated T cells when the receptor is activated by the peptide OVA 323-339. OT-II mice were injected on day 1 intraperitoneally with OVA 323-339 peptide (0.5 g/L) or vehicle [Al(OH) 3 ; 2.5 g], and hydralazine was administered in the drinking water during the 7 days. Blood pressure was not significantly changed between groups [OVA, 122Ϯ5.7; Al(OH) 3 , 122 Ϯ.76 mm Hg; hydralazineϩOVA: 113Ϯ1.3 mm Hg; hydral-azineϩAl(OH) 3 , 113Ϯ10.1 mm Hg]. In control mice, OVA markedly enhanced T-cell activation, as evidenced by an increase in CD69 and in CD44 high expressed on CD4 ϩ cells ( Figure 6A and 6B) compared to OT-II mice treated with vehicle Al(OH) 3 . Treatment of OT-II mice with hydralazine for 1 week did not diminish T-cell activation evoked by OVA ( Figure 6A and 6B) . These results indicate that hydralazine does not impair T-cell activation in response to a nonhypertensive stimulus.
Discussion
The purpose of this study was to investigate the potential mechanisms by which Ang II increases blood pressure and T-cell activation. Anteroventral third cerebral ventricle (AV3V) ablation of the forebrain, which is known to prevent the central actions of Ang II, was found to prevent activation of circulating T cells and to inhibit the vascular inflammation caused by this octapeptide. In contrast, AV3V lesions did not alter the effect of norepinephrine on these parameters. AV3V lesioning also prevented the increase in vascular O 2 Ϫ⅐ production caused by Ang II infusion. The antiinflammatory effects of AV3V lesioning could have been attributable to a reduction of neurohumoral stimuli or to prevention of pressure-induced tissue damage. Hydralazine, which prevented the hypertensive response to Ang II infusion, also prevented T-cell activation, vessel infiltration of leukocytes, and vascular superoxide production. In contrast, hydralazine did not block T-cell activation in response to a nonhypertensive stimulus in OT-II transgenic mice. This suggests that the reduction in T-cell activation and vascular infiltration caused by hydralazine during Ang II and norepinephrine infusion were likely a result of its blood pressure lowering effects rather than any direct actions it has on T cells. Our results suggest that Ang II-mediated hypertension is caused by central mechanisms and that T-cell activation is likely dependent on mechanical stimuli caused by elevations of arterial pressure induced by these central signals.
Before the present study, it was unknown whether T-cell activation and vascular infiltration in Ang II-induced hypertension was attributable to the direct effects of Ang II on T cells or whether T-cell activation was mediated by its CNS actions. To address this question, we created lesions of the AV3V region, which encompasses the OVLT, the ventral portion of the median preoptic nucleus (MnPO), and the preoptic periventricular nuclei. 5 The AV3V region receives input from other circumventricular structures, such as the subfornical organ, which transduces peripheral angiotensin signals and sends them to the AV3V, thus contributing to the development of hypertension. 20, 21 These regions of the brain have a poorly formed blood brain barrier and are capable of responding to circulating hormones such as Ang II 22, 23 and modulating its central actions, which include drinking behavior, vasopressin secretion, sympathetic activity, and norepinephrine synthesis. 5, 24 Our studies confirm these effects in that the increase in blood pressure following systemic Ang II infusion was attenuated after AV3V ablation. Interestingly, AV3V lesioning also prevented activation of circulating T cells and vascular inflammation caused by Ang II. Thus, these results indicate that the central actions of Ang II contribute to its proinflammatory effects.
To demonstrate that the reduction of T-cell activation after AV3V lesioning was not a nonspecific effect of this intervention, we performed additional studies in which we infused norepinephrine. We reasoned that one of the major effects of AV3V lesioning was to abolish sympathetic outflow to the periphery and that this, therefore, could be bypassed by administration of norepinephrine, a peripherally acting vasoconstrictor stimulus. The degree of blood pressure elevation, T-cell activation, and vascular infiltration of CD45 ϩ and CD3 ϩ cells in response to norepinephrine was similar in the absence and presence of AV3V lesioning. These results demonstrate that AV3V lesioning does not nonspecifically block the inflammatory response to all hypertensive stimuli and verifies the specificity for the central actions of Ang II. Moreover, these experiments with norepinephrine demonstrate that other vasoconstrictor stimuli are capable of mediating vascular inflammation during hypertension.
Ang II is known to promote sympathetic outflow and therefore one interpretation of our results is that immune cell activation is dependent on sympathetic activation and catecholamine release. T cells possess adrenergic receptors, and sympathetic nerves richly innervate lymphatic tissues. 25 Ang II could, therefore, stimulate T cells via activation of the sympathetic nervous system. These considerations are in keeping with the findings of Ganta et al, who showed that Ang II administration in the lateral cerebral ventricle increased splenic sympathetic nerve activity, which, in turn, causes increased mRNA expression of various proinflammatory cytokines in splenocytes. Splenic sympathetic denervation abrogated these responses, thus clearly linking the central effects of Ang II to peripheral immune activation and cytokine production. 26 Given the above considerations, it is possible that the consequent release of central mediators in response to Ang II, such as catecholamines, could directly lead to T-cell activation in the absence of blood pressure elevation. To address this, we performed studies using hydralazine to prevent hypertension during Ang II and norepinephrine infusion. The results of these studies suggest that pressure elevation per se could lead to T-cell activation and vascular infiltration. In contrast to AV3V lesioning, hydralazine activates the sympathetic nervous system, 27 in part via baroreflex-mediated mechanisms, but in the present study, it completely prevented T-cell activation. These results would seem to exclude a direct effect of sympathetic nerves on T-cell activation and would favor an effect of pressure per se in T-cell activation.
We have previously found that hydralazine inhibits the NADPH oxidase. 28 The NADPH oxidase has been identified in T cells, 29 and its blockade might have prevented T-cell activation. Hydralazine also opens calcium-sensitive potassium channels, 30 which are present in T cells, 31 and, therefore, may have direct effects on T-cell function. To determine whether hydralazine directly inhibits T-cell activation in response to nonhypertensive stimuli, we studied OT-II transgenic mice. These animals express a T-cell receptor that leads to CD4 ϩ cell activation in response to OVA peptide administration. We found that hydralazine did not block T-cell activation caused by OVA peptide administration in these animals, suggesting that it does not prevent T-cell activation by stimuli that do not cause hypertension. These findings support the notion that the effect of hydralazine during Ang II infusion was not attributable to a direct effect of the drug on T cells but more likely to its prevention of hypertension. We are not completely able, however, to delineate a direct effect of neurohumoral mediators, such as catecholamines, from mechanical stimuli caused by pressure elevation. Our findings are nevertheless compatible with a scenario in which the central effects of Ang II lead to pressure elevation, which, in turn, promotes T-cell activation and vascular inflammation.
These results should not be taken to indicate that inflammation, and in particular T-cell activation, is simply a result of hypertension and does not contribute to blood pressure elevation. As we previously demonstrated, in the absence of T cells, the hypertensive response to Ang II and DOCA-salt challenge is minimal. 9 Our present findings suggest, however, that a modest increase in blood pressure may lead to an inflammatory response that further increases and sustains blood pressure in a feed-forward fashion (Online Figure III) . This might explain the propensity of prehypertension to progress to overt hypertension. These considerations stress the benefit of lowering blood pressure by virtually any means to prevent and reverse this mechanism. 
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